Director of Health Economics Outcomes Research
ArineFull Time
Expert & Leadership (9+ years)
Candidates must possess a Master's Degree (MS, MPH, PharmD, PhD) in a relevant discipline such as health economics, medicine, pharmacy, public health, or epidemiology. A minimum of 10 years of experience in the healthcare or pharmaceutical industry is required, with at least 7 of those years specifically in Health Economics and Outcomes Research (HEOR).
The Senior Director, HEOR/RWE will lead the development of integrated HEOR and evidence generation strategies and tactical plans for therapeutic programs. This includes conducting evidence gap analyses, designing and executing real-world evidence studies, and overseeing the development of publications and presentations. The role involves supporting global market access strategies, collaborating with cross-functional teams on evidence packages for payers, and managing HEOR budgets and external research partners. Additionally, the position requires monitoring and interpreting U.S. policy changes and translating their implications into actionable HEOR strategies.
Develops treatments for neurodegenerative diseases
Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials to assess its effectiveness. The CENTAUR ALS trial showed promising results for ALS patients, using a randomized, double-blind, placebo-controlled design to ensure reliable outcomes. They are also conducting the PEGASUS trial to evaluate AMX0035's safety and effectiveness in Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes and enhance the quality of life for individuals suffering from neurodegenerative conditions.